BlackRock’s Vaxxinity, Inc. Class A Common Stock VAXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-2,623,052
Closed -$1.88M 5410
2024
Q1
$1.88M Sell
2,623,052
-90,864
-3% -$65.9K ﹤0.01% 4014
2023
Q4
$2.31M Buy
2,713,916
+186,965
+7% +$181K ﹤0.01% 3990
2023
Q3
$3.46M Buy
2,526,951
+154,943
+7% +$336K ﹤0.01% 3807
2023
Q2
$5.98M Buy
2,372,008
+1,998,747
+535% +$4.23M ﹤0.01% 3652
2023
Q1
$847K Hold
373,261
﹤0.01% 4382
2022
Q4
$523K Hold
373,261
﹤0.01% 4594
2022
Q3
$739K Buy
+373,261
New +$777K ﹤0.01% 4588

Other funds holding VAXX

BlackRock's VAXX Position: Q2 2024 in Review

BlackRock sold out of Vaxxinity, Inc. Class A Common Stock (VAXX) in Q2 2024, closing a stake of 2,623,052 shares — an estimated $1.88M sold.

BlackRock first reported a position in VAXX in Q3 2022 and held it in 7 quarters. The position peaked at $5.98M in Q2 2023. 8 funds tracked by Wall St. Rank hold VAXX as of Q2 2024.

  • BlackRock reported no remaining Vaxxinity, Inc. Class A Common Stock position as of Q2 2024 after selling out during the quarter.
  • BlackRock sold 2,623,052 Vaxxinity, Inc. Class A Common Stock shares in Q2 2024, an estimated $1.88M.
  • BlackRock first reported a position in Vaxxinity, Inc. Class A Common Stock in Q3 2022 and held it in 7 quarters.
  • BlackRock's Vaxxinity, Inc. Class A Common Stock position peaked at $5.98M in Q2 2023.
  • 8 funds tracked by Wall St. Rank held Vaxxinity, Inc. Class A Common Stock as of Q2 2024.

Based on BlackRock's 13F filing for Q2 2024, filed 13 Aug 2024.